A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Summary

This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in combination with Toripalimab. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in combination with Toripalimab to subjects with advanced solid tumors.

Timeline

Start

2020-04-21

Primary completion

2022-10-19

Completion

2022-10-19

Drugs

Indications